NEFL and multiple sclerosis: This latter group, based upon data from the phase 2 RCT of ibudilast and an open-label study of high-dose biotin, again supports the notion of NFL primarily being a marker of neuroinflammation, rather than neurodegeneration, in multiple sclerosis.